Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer

Based on our previous phase II clinical trial of anti-programmed death-1 (PD-1) antibody nivolumab for platinum-resistant ovarian cancer (n = 19, UMIN000005714), we aimed to identify the biomarkers predictive of response. Tumor gene expression was evaluated by proliferative, mesenchymal, differentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Ryusuke, Hamanishi, Junzo, Brown, J. B., Abiko, Kaoru, Yamanoi, Koji, Taki, Mana, Hosoe, Yuko, Yamaguchi, Ken, Baba, Tsukasa, Matsumura, Noriomi, Konishi, Ikuo, Mandai, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169687/
https://www.ncbi.nlm.nih.gov/pubmed/34075161
http://dx.doi.org/10.1038/s41598-021-91012-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169687/
https://www.ncbi.nlm.nih.gov/pubmed/34075161
http://dx.doi.org/10.1038/s41598-021-91012-w

Ejemplares similares